首页> 美国卫生研究院文献>Molecules >In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile
【2h】

In Search of Outliers. Mining for Protein Kinase Inhibitors Based on Their Anti-Proliferative NCI-60 Cell Lines Profile

机译:寻找异常值。基于其抗增殖NCI-60细胞系谱的蛋白激酶抑制剂的挖掘

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Protein kinases play a pivotal role in signal transduction, protein synthesis, cell growth and proliferation. Their deregulation represents the basis of pathogenesis for numerous diseases such as cancer and pathologies with cardiovascular, nervous and inflammatory components. Protein kinases are an important target in the pharmaceutical industry, with 48 protein kinase inhibitors (PKI) already approved on the market as treatments for different afflictions including several types of cancer. The present work focuses on facilitating the identification of new PKIs with antitumoral potential through the use of data-mining and basic statistics. The National Cancer Institute (NCI) granted access to the results of numerous previously tested compounds on 60 tumoral cell lines (NCI-60 panel). Our approach involved analyzing the NCI database to identify compounds that presented similar growth inhibition (GI) profiles to that of existing PKIs, but different from approved oncologic drugs with other mechanisms of action, using descriptive statistics and statistical outliers. Starting from 34,000 compounds present in the database, we filtered 400 which displayed selective inhibition on certain cancer cell lines similar to that of several already-approved PKIs.
机译:蛋白激酶在信号转导,蛋白合成,细胞生长和增殖中起关键作用。它们的失调代表了许多疾病的发病机理的基础,例如癌症以及具有心血管,神经和炎性成分的病理。蛋白激酶是制药行业的重要目标,市场上已经批准了48种蛋白激酶抑制剂(PKI)作为治疗包括多种类型癌症在内的各种疾病的方法。本工作着重于通过使用数据挖掘和基本统计​​数据来促进新的具有抗肿瘤潜力的PKI的识别。美国国家癌症研究所(NCI)允许访问60种肿瘤细胞系上许多先前测试过的化合物的结果(NCI-60组)。我们的方法涉及分析NCI数据库,以使用描述性统计和统计异常值来鉴定具有与现有PKI相似的生长抑制(GI)谱,但不同于具有其他作用机理的已批准的肿瘤药物的化合物。从数据库中存在的34,000种化合物开始,我们过滤了400种对某些癌细胞系表现出选择性抑制作用的药物,类似于几种已获批准的PKI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号